Volume | 27,112 |
|
|||||
News | - | ||||||
Day High | 13.27 | Low High |
|||||
Day Low | 12.40 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Greenwich LifeSciences Inc | GLSI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
12.59 | 12.40 | 13.27 | 12.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
563 | 27,112 | $ 12.88 | $ 349,290 | - | 7.58 - 21.44 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:22:37 | 1 | $ 12.77 | USD |
Greenwich LifeSciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
166.51M | 12.85M | - | 0 | -7.83M | -0.61 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Greenwich LifeSciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLSI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 14.27 | 14.70 | 11.375 | 12.83 | 39,290 | -1.31 | -9.18% |
1 Month | 19.90 | 21.44 | 11.375 | 16.14 | 38,473 | -6.94 | -34.87% |
3 Months | 9.13 | 21.44 | 8.00 | 14.41 | 54,175 | 3.83 | 41.95% |
6 Months | 8.16 | 21.44 | 7.58 | 13.25 | 34,527 | 4.80 | 58.82% |
1 Year | 11.50 | 21.44 | 7.58 | 12.16 | 26,524 | 1.46 | 12.70% |
3 Years | 36.69 | 48.96 | 6.8241 | 18.47 | 70,823 | -23.73 | -64.68% |
5 Years | 5.00 | 158.07 | 3.262 | 36.98 | 163,373 | 7.96 | 159.20% |
Greenwich LifeSciences Description
Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels. |